TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
Open Access
- 20 October 2023
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 9 (1) , 1-11
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive type of breast cancer with a poor prognosis and a high recurrence rate. Chemotherapy is still the mainstay of treatment for cancer patients without a genetic BRCA mutation, despite the approval of Olaparib, an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. Tripartite motif containing-21 (TRIM21) is one of the TRIM family members that has been investigated in various types of cancer. Here, we found that a low TRIM21 expression level was correlated with poor overall survival of TNBC patients. Knockout of TRIM21 promoted the proliferation of TNBC cells in vivo and in vitro, as well as migratory and invasive capabilities in vitro. Importantly, breast cancer susceptibility gene 1 (BRCA1) was identified as a ubiquitination substrate of TRIM21. It was confirmed that BRCA1 was upregulated after Olaparib treatment, which may explain the relative resistance of BRCA1-proficient TNBC cells to Olaparib. Moreover, Sorafenib, a standard treatment for hepatocellular carcinoma, increased the sensitivity of TNBC cells to Olaparib by promoting TRIM21-mediated ubiquitination degradation of BRCA1. Thus, a synergic effect of Olaparib and Sorafenib was found in vitro and in vivo. This combined treatment also aggravated DNA damage, cell cycle arrest, and apoptosis of TNBC cells. In summary, the findings verified the synergistic effect of Olaparib and Sorafenib and revealed TRIM21 as a potential target for TNBC therapy.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Shanghai Municipality (20ZR140710)
This publication has 29 references indexed in Scilit:
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesAnnals of Oncology, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 2011
- How basal are triple‐negative breast cancers?International Journal of Cancer, 2008
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Molecular portraits of human breast tumoursNature, 2000
- Role of the human RAD51 protein in homologous recombination and double-stranded-break repairTrends in Biochemical Sciences, 1998
- GENETICS OF NATURAL POPULATIONS. XIII. RECOMBINATION AND VARIABILITY IN POPULATIONS OF DROSOPHILA PSEUDOOBSCURAGenetics, 1946